{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:18:35Z","timestamp":1784953115655,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T00:00:00Z","timestamp":1255737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00228-009-0739-z","type":"journal-article","created":{"date-parts":[[2009,10,16]],"date-time":"2009-10-16T09:50:54Z","timestamp":1255686654000},"page":"199-206","source":"Crossref","is-referenced-by-count":35,"title":["Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents"],"prefix":"10.1007","volume":"66","author":[{"given":"Carlo","family":"Piccinni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sacripanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Motola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Montanaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,17]]},"reference":[{"key":"739_CR1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00019052-200406000-00019","volume":"17","author":"IJ Koralnik","year":"2004","unstructured":"Koralnik IJ (2004) New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 17:365\u2013370","journal-title":"Curr Opin Neurol"},{"key":"739_CR2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ana.20933","volume":"60","author":"IJ Koralnik","year":"2006","unstructured":"Koralnik IJ (2006) Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 60:162\u2013173","journal-title":"Ann Neurol"},{"key":"739_CR3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375\u2013381","journal-title":"N Engl J Med"},{"key":"739_CR4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369\u2013374","journal-title":"N Engl J Med"},{"key":"739_CR5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Assche Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353:362\u2013368","journal-title":"N Engl J Med"},{"key":"739_CR6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"TA Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, Clifford DB (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924\u2013933","journal-title":"N Engl J Med"},{"key":"739_CR7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"739_CR8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11910-007-0072-9","volume":"7","author":"JR Berger","year":"2007","unstructured":"Berger JR (2007) Progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep 7:461\u2013469","journal-title":"Curr Neurol Neurosci Rep"},{"key":"739_CR9","unstructured":"U.S. Food and Drug Administration (FDA) (2009) FDA-AERS Adverse Event Reporting System. http:\/\/www.fda.gov\/cder\/aers\/default.htm . Accessed 23 Feb 2009"},{"key":"739_CR10","unstructured":"Northrup Grumman (2009) The Medical Dictionary for Regulatory Activities (MedDRA). Available via http:\/\/www.meddramsso.com\/MSSOWeb\/index.htm . Accessed 23 Feb 2009"},{"key":"739_CR11","unstructured":"World Health Organization (WHO) (2009) WHO-VigiBase.Uppsala Monitoring Centre. http:\/\/www.umc-products.com\/DynPage.aspx?id=4910&mn=1107 . Accessed 23 Feb 2009"},{"key":"739_CR12","unstructured":"World Health Organization (WHO) (2009) WHO Collaborating Centre for Drug Statistics Methodology. http:\/\/www.whocc.no\/atcddd\/ . Accessed 23 Feb 2009"},{"key":"739_CR13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/14740338.6.6.713","volume":"6","author":"IW Hammond","year":"2007","unstructured":"Hammond IW, Gibbs TG, Seifert HA, Rich DS (2007) Database size and power to detect safety signals in pharmacovigilance. Expert Opin Drug Saf 6:713\u2013721","journal-title":"Expert Opin Drug Saf"},{"key":"739_CR14","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1001\/archinte.166.18.1938","volume":"166","author":"CD Furberg","year":"2006","unstructured":"Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL (2006) The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med 166:1938\u20131942","journal-title":"Arch Intern Med"},{"key":"739_CR15","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 30:891\u2013898","journal-title":"Drug Saf"},{"key":"739_CR16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/00002018-200831070-00006","volume":"31","author":"D Motola","year":"2008","unstructured":"Motola D, Vargiu A, Leone R, Conforti A, Moretti U, Vaccheri A, Velo G, Montanaro N (2008) Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. Drug Saf 31:609\u2013616","journal-title":"Drug Saf"},{"key":"739_CR17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","volume":"24","author":"NR Hartnell","year":"2004","unstructured":"Hartnell NR, Wilson JP (2004) Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 24:743\u2013749","journal-title":"Pharmacotherapy"},{"key":"739_CR18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00002018-200730060-00009","volume":"30","author":"M Hauben","year":"2007","unstructured":"Hauben M, Reich L, DeMicco J, Kim K (2007) \u2018Extreme duplication\u2019 in the US FDA Adverse Events Reporting System database. Drug Saf 30:551\u2013554","journal-title":"Drug Saf"},{"key":"739_CR19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/QAI.0b013e31817bec64","volume":"49","author":"V Falco","year":"2008","unstructured":"Falco V, Olmo M, del Saz SV, Guelar A, Santos JR, Gutierrez M, Colomer D, Deig E, Mateo G, Montero M, Pedrol E, Podzamczer D, Domingo P, Llibre JM (2008) Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 49:26\u201331","journal-title":"J Acquir Immune Defic Syndr"},{"key":"739_CR20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.nrl.0000250948.04681.96","volume":"12","author":"AJ Aksamit","year":"2006","unstructured":"Aksamit AJ (2006) Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist 12:293\u2013298","journal-title":"Neurologist"},{"key":"739_CR21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","volume":"30","author":"EJ Boren","year":"2008","unstructured":"Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME (2008) The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 30:90\u201398","journal-title":"J Autoimmun"},{"key":"739_CR22","unstructured":"U.S. Food and Drug Administration (FDA) (2006) Tysabri - FDA approval letter. http:\/\/www.fda.gov\/cder\/foi\/appletter\/2006\/125104s015LTR.pdf . Accessed 23 Feb 2009"},{"key":"739_CR23","unstructured":"U.S. Food and Drug Administration (FDA) (2006) Tysabri - risk minimization action plan. http:\/\/www.fda.gov\/cder\/foi\/appletter\/2006\/125104s015LTR.pdf . Accessed 23 Feb 2009"},{"issue":"Suppl 2","key":"739_CR24","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1007\/s10072-008-0948-8","volume":"29","author":"GL Mancardi","year":"2008","unstructured":"Mancardi GL, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Provinciali L, Rossi P, Savettieri G, Tedeschi G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Addis A, Martini N (2008) Natalizumab: a country-based surveillance program. Neurol Sci 29(Suppl 2):S235\u2013S237","journal-title":"Neurol Sci"},{"key":"739_CR25","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.300.16.1887","volume":"300","author":"TJ Giezen","year":"2008","unstructured":"Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC (2008) Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300:1887\u20131896","journal-title":"JAMA"},{"key":"739_CR26","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"KR Carson","year":"2009","unstructured":"Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 10:816\u2013824","journal-title":"Lancet Oncol"},{"key":"739_CR27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/tx800389u","volume":"22","author":"J Uetrecht","year":"2009","unstructured":"Uetrecht J (2009) Immune-mediated adverse drug reactions. Chem Res Toxicol 22:24\u201334","journal-title":"Chem Res Toxicol"},{"key":"739_CR28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.bor.0000127594.92432.7c","volume":"16","author":"CD Hamilton","year":"2004","unstructured":"Hamilton CD (2004) Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 16:393\u2013398","journal-title":"Curr Opin Rheumatol"},{"key":"739_CR29","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275\u20132285","journal-title":"JAMA"},{"key":"739_CR30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301:737\u2013744","journal-title":"JAMA"},{"key":"739_CR31","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911\u2013923","journal-title":"N Engl J Med"},{"key":"739_CR32","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353:1912\u20131925","journal-title":"N Engl J Med"},{"key":"739_CR33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1474-4422(08)70281-3","volume":"8","author":"HP Hartung","year":"2009","unstructured":"Hartung HP (2009) New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 8:28\u201331","journal-title":"Lancet Neurol"},{"key":"739_CR34","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA) (2009) European Medicines Agency recommends suspension of the marketing authorisation ofRaptiva (efalizumab). EMEA\/CHMP\/20857\/2009. http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/raptiva\/2085709en.pdf . Accessed 1 Apr 2009"},{"key":"739_CR35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.md.0000230250.95281.60","volume":"85","author":"VC Wu","year":"2006","unstructured":"Wu VC, Huang JW, Lien HC, Hsieh ST, Liu HM, Yang CC, Lin YH, Hwang JJ, Wu KD (2006) Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. Medicine (Baltimore) 85:203\u2013213","journal-title":"Medicine (Baltimore)"},{"key":"739_CR36","unstructured":"National Institute for Health and Clinical Excellence (NICE) (2007) Natalizumab for the treatment of adults with highly active relapsing- remitting multiple sclerosis. www.nice.org.uk"},{"key":"739_CR37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000156599","volume":"217","author":"L Naldi","year":"2008","unstructured":"Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Maccarone M, Chatenoud L, Bertuccio P, Maggese E, Cuscito R (2008) Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 217:365\u2013373","journal-title":"Dermatology"},{"key":"739_CR38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000156598","volume":"217","author":"T Nijsten","year":"2008","unstructured":"Nijsten T, Wakkee M (2008) Psocare: Italy shows the way in postmarketing studies. Dermatology 217:362\u2013364","journal-title":"Dermatology"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0739-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0739-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0739-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:52:02Z","timestamp":1558702322000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0739-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,17]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0739-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,17]]}}}